Toong Youttananukorn: WE CARE Study From India Showing the Needs of Patients and Caregivers
Toong Youttananukorn, Data Quality Manager at World Federation of Hemophilia, shared World Federation of Hemophilia’s post on LinkedIn, adding:
”Proud to see a World Bleeding Disorders Registry (WBDR) Research Support Program (RSP) project in a peer-reviewed publication.
The WE CARE study from Christian Medical College and Hospital in Ludhiana, India is a reminder that local data tells stories global datasets can’t – documenting chronic pain, financial strain, stigma, and isolation affecting patients and caregivers alike in a resource-limited setting.
This is exactly what the WBDR RSP was designed for: HTCs doing rigorous research on the questions that matter most to their communities.
The result is not just a publication. It is the evidence that holistic, patient-centred care models are needed, and a foundation for advocating for Treatment For All.
Congratulations to the team at CMC Ludhiana DMridul Makkar Bothra PT, M Joseph John, Diksha Sarwan PT.”
World Federation of Hemophilia (WFH) shared a post on LinkedIn about a recent article by Mridul Makkar et al., published in the Haemophilia:
”New research supported by the WFH World Bleeding Disorders Registry (WBDR) Research Support Program has been published in Haemophilia, the official journal of the WFH.
The WECARE study highlights the personal, social, and economic challenges faced by people living with hemophilia and their caregivers, from chronic pain and disrupted education or work to financial strain and stigma.
Findings like these help strengthen the case for more holistic care that supports the full realities of living with bleeding disorders.”
Title: Personal, Social, Economic Impacts on Haemophilia A Patients and Caregivers: A Mixed Method Study (WE CARE)
Authors: Mridul Makkar, M Joseph John, Diksha Sarwan, Soumya Ojha, Ranjit Injety, Manasi Gupta, Himanshu Aggarwal
Stay updated with Hemostasis Today.
-
Sep 3, 2026, 10:56Elias Othman: Can an Enzyme Involved in Cell Signaling Become a Target for Antithrombotic Drug Discovery?
-
Sep 3, 2026, 10:42Jared Griffard: Hemorrhagic Shock and Component Blood Transfusion
-
Sep 3, 2026, 10:31Alan Nurden: Comparing Antiplatelet and Antithrombin Therapies in Coronary Microcirculation
-
Sep 3, 2026, 08:53Jamie’s Journey Through a Decade with Immune Thrombocytopenia – ITP Support Association
-
Sep 3, 2026, 08:00Beth Meneley: When Transfusion Is Not an Option – HBOT for Exceptional Blood Loss Anemia
-
Sep 3, 2026, 06:27Seyed Mehrab Safdari: Unmasking Factor VII Padua to Prevent Unnecessary Therapy and Thrombotic Risk
-
Sep 3, 2026, 04:09Pedro Perez: Are We Entering a New Era in the Treatment of Intermediate-High-Risk PE?
-
Sep 3, 2026, 04:01Marianne Yee: Supporting Families and Transformative Therapies in Sickle Cell Disease
-
Sep 3, 2026, 03:51Strengthening Bleeding Disorders Care in New Zealand – WFH